ADCs help define AstraZeneca’s next oncology chapter

Antibody-drug conjugates are again big newsmakers at ASCO, and AstraZeneca — with partner Daiichi Sankyo — is one of the companies leading the charge to bring the modality into broader patient populations.

At the 2023 American Society of Clinical Oncology conference, a pair of TROP2-targeted ADCs made progress in non-small cell lung cancer (NSCLC), a new indication for the drug class, while Enhertu trastuzumab deruxtecan is proving its value beyond the breast, gastric and lung cancer populations it already addresses with data from a tumor-agnostic study...